Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal
184.54
+0.68 (0.37%)
Real-time:   2:19PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 183.18 - 185.11
52 week 150.06 - 203.30
Open 184.00
Vol / Avg. 775,891.00/2.22M
Mkt cap 41.53B
P/E 63.19
Div/yield     -
EPS 2.92
Shares 225.81M
Beta 0.56
Inst. own 87%
Jul 22, 2015
Q2 2015 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 10, 2015
Alexion Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 9, 2015
Alexion Pharmaceuticals Inc at William Blair Annual Growth Stock Conference
May 27, 2015
Alexion Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference
May 13, 2015
Alexion Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Alexion Pharmaceuticals Inc Annual Shareholders Meeting
May 6, 2015
Alexion Pharmaceuticals Inc at Deutsche Bank Health Care Conference
Apr 23, 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Call
Apr 23, 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 15.21% 29.41%
Operating margin 17.27% 38.89%
EBITD margin - 43.10%
Return on average assets 8.50% 17.47%
Return on average equity 10.74% 23.11%
Employees 2,273 -
CDP Score - -

Address

352 Knotter Dr
CHESHIRE, CT 06410-1138
United States - Map
+1-203-7761790 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Company's product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Company's preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
David L Hallal Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 48
Bio & Compensation  - Reuters
Dominique Monnet Senior Vice President, Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 50
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 45
Bio & Compensation  - Reuters